Compare TOP & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOP | PSNL |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2021 | 2019 |
| Metric | TOP | PSNL |
|---|---|---|
| Price | $15.82 | $14.35 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.17 |
| AVG Volume (30 Days) | 232.8K | ★ 2.2M |
| Earning Date | 07-07-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.25 | 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | $4,723,765.00 | ★ $69,648,000.00 |
| Revenue This Year | N/A | $27.28 |
| Revenue Next Year | N/A | $24.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 41.89 | N/A |
| 52 Week Low | $1.85 | $4.96 |
| 52 Week High | $17.99 | $18.89 |
| Indicator | TOP | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 54.21 | 24.63 |
| Support Level | $13.96 | $13.68 |
| Resistance Level | $16.63 | $14.81 |
| Average True Range (ATR) | 1.71 | 0.35 |
| MACD | 0.36 | -0.14 |
| Stochastic Oscillator | 71.98 | 1.93 |
TOP Financial Group Ltd is operates as an online brokerage firm in Hong Kong specializing in the trading of local and overseas equities, futures, and options products. It conduct the futures and stock brokerage business through three trading platforms, Esunny for futures trading and Longbridge for stock trading, all of which were licensed from third parties and can be easily accessed through its application, or APP, software, and websites. The three platforms are designed for seamless, efficient, and secure trading platform. The company operates and manages its business as a single operating and reportable segment.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.